fulvestrant has been researched along with Parkinsonian Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bourque, M; Di Paolo, T; Morissette, M | 1 |
| Annepu, J; Diwakar, L; Kenchappa, RS; Ravindranath, V | 1 |
2 other study(ies) available for fulvestrant and Parkinsonian Disorders
| Article | Year |
|---|---|
Neuroprotection in Parkinsonian-treated mice via estrogen receptor α activation requires G protein-coupled estrogen receptor 1.
Topics: Animals; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Corpus Striatum; Dopamine; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Estrogen Receptor beta; Estrogens; Fulvestrant; Male; Mice, Inbred C57BL; Neuroprotective Agents; Parkinsonian Disorders; Receptors, Estrogen; Receptors, G-Protein-Coupled; Steroids | 2015 |
Estrogen and neuroprotection: higher constitutive expression of glutaredoxin in female mice offers protection against MPTP-mediated neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Electron Transport Complex I; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Glutaredoxins; Glutathione; Male; Mesencephalon; Mice; Mitochondria; Nerve Tissue Proteins; Neurotoxins; Oxidoreductases; Parkinsonian Disorders; Receptors, Estrogen; Sex Characteristics; Tyrosine 3-Monooxygenase; Ubiquinone | 2004 |